Barinthus Biotherapeutics plc (BRNS) — Cash Flow Quality Index

Latest as of September 2022: 1.45x

Barinthus Biotherapeutics plc (BRNS) has a Cash Flow Quality Index of 1.45x as of September 2022. Operating cash flow of $11.88 Million exceeds net income of $8.22 Million, indicating high earnings quality where cash backs reported profits. Explore Barinthus Biotherapeutics plc (BRNS) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

1.45x
Operating CF / Net Income

Operating Cash Flow

$11.88 Million
USD

Net Income

$8.22 Million
USD

Data as of

Sep 2022
Most recent filing

Barinthus Biotherapeutics plc Cash Flow Quality Index (2022–2022)

Historical Cash Flow Quality Index for Barinthus Biotherapeutics plc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see BRNS cash flow conversion.

Annual Cash Flow Quality Index for Barinthus Biotherapeutics plc (2022–2022)

Year-by-year earnings quality comparison for Barinthus Biotherapeutics plc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2022 -2.71x $-14.43 Million $5.32 Million —
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.